Table 1.
Summary of the Clinical, Pathological and Survival Data of the Patients in Each Study.
| Article (country) | No. of patients (M/F) | Median age (years) | Primary cases | Cirrhosis/HBV/HCV | No. of tumours | Tumour size (cm) | RFA/MWA | OS (months) | 1/3/5-year survival (%) |
|---|---|---|---|---|---|---|---|---|---|
| Xu et al27 (CN) | 18 (13/5) | 60 | 8/18 | – | 25 | 2.80a | 12/6 | 8.7 | 36.3/30.3/30.3 |
| Fu et al28 (CN) | 17 (9/8) | 54.5 | 7/17 | 5/–/– | 26 | 4.40b | 17/0 | 33.9 | 84.6/43.3/28.9 |
| Kim et al29 (KR) | 20 | 61 | 0/20 | –/6/1 | 29 | 1.50b | 20/0 | 19.5 | 70.0/21/– |
| Yu et al30 (CN) | 15 (11/4) | 60 | 15/15 | –/5/1 | 24 | 3.20a | 0/15 | 10.0 | 60.0/–/– |
| Haidu et al31 (AT) | 17 (12/5) | 62 | 8/17 | – | 26 | 4.20c | 17/0 | 52.4 | 82.2/64.7/47.1 |
| Zhang et al32 (CN) | 77 (58/19) | 51.2 | 0/77 | 22/–/– | 133 | – | –d | 21.3 | 69.8/20.5/– |
| Kim et al33 (KR) | 13 (10/3) | 13/13 | – | 17 | 2.50c | 13/0 | 27.4 | 85.0/51.0/15.0 | |
| Giorgio et al34 (IT) | 10 (5/5) | 70 | 9/10 | –/1/3 | 12 | 3.00 | 10/0 | 19.5c | 100/83.3/83.3 |
| Fu et al35 (CN) | 12 | 0/12 | –/2/– | 19 | 3.20b | 12/0 | 30.0 | 87.5/37.5/– | |
| Butros et al36 (USA) | 7 (3/4) | 65 | 1/7 | – | 9 | 2.30c | 7/0 | 35.0e | 100/60.0/20.0 |
AT: Austria; CN: China; IT: Italy; KR: Korea; USA: United States of America; HBV: hepatitis B virus; HCV: hepatitis C virus; RFA: radiofrequency ablation; MWA: microwave ablation; OS: overall survival.
a
Mean tumour size: typically values indicated as median values unless otherwise indicated.
b
Value indicative of the mean/median of largest tumour sizes of patients.
c
Data not provided ad numerum in the study but calculated using available data.
d
Number unspecified.
e
Excludes one patient lost to follow-up.